MedMatrix Rx
Daily 340B Morning Briefing for Executives
Recent developments in the 340B program highlight significant changes and challenges for covered entities. Johnson & Johnson has mandated that covered entities submit claims-level data for outpatient drugs, effective September 15, 2026. This move is part of a broader trend as the American Hospital Association seeks a permanent ban on rebate models in the 340B program, citing operational burdens. Additionally, a federal pilot program set to launch in 2027 will introduce rebates for 340B drugs, which could impact hospital cash flow and staffing. A report indicates that 340B hospitals are spending a smaller share of their budgets on charity care compared to their non-340B counterparts, raising questions about the program’s effectiveness and the allocation of resources. These developments reflect the evolving landscape of the 340B program and its implications for healthcare providers.
EXECUTIVE SUMMARY
01
Johnson & Johnson mandates claims data for 340B pricing.
J&J requires 340B covered entities to submit claims-level data for outpatient drugs, effective September 15, 2026.
J&J requires 340B covered entities to submit claims-level data for outpatient drugs, effective September 15, 2026.
Source: Becker’s Hospital Review
02
Federal rebate pilot to start in 2027 for 340B drugs.
A federal pilot launching January 1, 2027, will allow 340B pricing through rebates, affecting hospital cash flow and staffing.
A federal pilot launching January 1, 2027, will allow 340B pricing through rebates, affecting hospital cash flow and staffing.
Source: Becker’s Hospital Review
03
340B hospitals report less charity care than non-340B peers.
A report finds 340B hospitals spend a smaller share of their budgets on charity care, raising questions about program effectiveness.
A report finds 340B hospitals spend a smaller share of their budgets on charity care, raising questions about program effectiveness.
Source: Medical Daily
04
AHA seeks permanent ban on 340B rebate models.
The American Hospital Association urges Congress to prohibit rebate models in the 340B program, citing operational burdens.
The American Hospital Association urges Congress to prohibit rebate models in the 340B program, citing operational burdens.
Source: Becker’s Hospital Review
05
ASHP advocates for 340B protections on Capitol Hill.
ASHP members push for expanded Medicare coverage and 340B program protections during congressional meetings.
ASHP members push for expanded Medicare coverage and 340B program protections during congressional meetings.
Source: Becker’s Hospital Review
06
NASP comments on CMS 340B payment changes.
The National Association of Specialty Pharmacy submits comments on proposed changes to Medicare reimbursement for 340B drugs.
The National Association of Specialty Pharmacy submits comments on proposed changes to Medicare reimbursement for 340B drugs.
Source: NASP
07
AstraZeneca v. Jackley case progresses in 8th Circuit.
AstraZeneca’s case against Marty Jackley sees a reply to a petition for initial hearing en banc filed on September 25, 2026.
AstraZeneca’s case against Marty Jackley sees a reply to a petition for initial hearing en banc filed on September 25, 2026.
Source: CourtListener — 8th Cir.
08
Novartis loses rehearing request in 8th Circuit case.
The 8th Circuit denied Novartis’s petition for rehearing en banc in its case against Catherine L. Hanaway.
The 8th Circuit denied Novartis’s petition for rehearing en banc in its case against Catherine L. Hanaway.
Source: CourtListener — 8th Cir.
EXECUTIVE SUMMARY — KEY TAKEAWAYS
Most important 340B implication. The mandate for claims-level data from Johnson & Johnson, along with the upcoming federal rebate pilot, poses significant implications for covered entities participating in the 340B program. As these entities adapt to new reporting requirements and potential changes in revenue streams, they may face increased administrative burdens and shifts in financial stability. The findings regarding reduced charity care spending among 340B hospitals further complicate the narrative, suggesting that while these entities benefit from discounted drug pricing, the intended purpose of the program—to provide access to care for underserved populations—may be undermined. This situation necessitates a reevaluation of how 340B savings are used and the need for transparency and accountability to ensure that the program effectively meets its goals.
Emerging risks.
- Non-compliance with J&J’s claims-data policy could lead to suspension of 340B pricing.
- The federal rebate pilot may disrupt hospital cash flow and require staffing adjustments.
- Oklahoma’s legal battle over its 340B law could set precedents affecting state-level regulations.
- 340B hospitals face scrutiny over charity care spending, impacting public perception and policy support.
Emerging opportunities.
- Hospitals can use the rebate pilot to improve claims transparency and reduce duplicate discounts.
- Engaging with J&J early on data submission issues may mitigate compliance risks.
- Advocacy for 340B protections on Capitol Hill could strengthen program support and funding.
- Participation in policy discussions on CMS payment changes offers a chance to influence future reimbursement models.
Key actions for providers.
- Review and update claims data systems to comply with J&J’s new requirements.
- Prepare for potential financial impacts of the 2027 rebate pilot by adjusting budget forecasts.
- Monitor Oklahoma’s appeal and similar state-level legal developments for regulatory changes.
- Engage with policymakers to advocate for a permanent 340B rebate ban and program protections.
TOP STORIES
Federal rebate pilot for 340B drugs starts 2027.
Becker’s Hospital Review · September 28, 2026
- Pilot allows rebates instead of upfront discounts for certain drugs.
- HRSA aims for improved transparency and reduced duplicate discounts.
- Scheduled to begin January 1, 2027.
FEDERAL POLICY & REGULATORY DEVELOPMENTS
AHA calls for permanent 340B rebate ban.
Becker’s Hospital Review · September 25, 2026
- AHA urges Congress to prohibit rebate models in 340B.
- SECURE 340B Act combines protections with new requirements.
- AHA warns of potential operational burdens on hospitals.
ASHP advocates for 340B protections.
Becker’s Hospital Review · September 16, 2026
- ASHP members meet with Congress for 340B protections.
- Legislation seeks expanded Medicare coverage for pharmacist services.
- Advocacy includes pharmacy residency training support.
340B PROGRAM DEVELOPMENTS
340B hospitals report less charity care than peers.
Medical Daily · September 28, 2026
- 340B hospitals spent 2.16% of expenses on charity care.
- Non-340B hospitals spent 2.82% on charity care.
- Report raises questions about 340B’s impact on patient assistance.
J&J’s 340B claims-data policy impacts covered entities.
Frier Levitt · September 22, 2026
- J&J requires claims data for 340B pricing access.
- Entities must submit data within 45-60 days of drug dispensing.
- Policy includes a single contract pharmacy limit.
LITIGATION & ENFORCEMENT WATCH
| Court | Matter | Date |
|---|---|---|
| 8th Cir. | Astrazeneca Pharmaceuticals, LP v. Marty Jackley — Reply to response to petition for initial hearing en banc. Case filed August 11, 2026. [source] | September 25, 2026 |
| 8th Cir. | Pharm. Res. & Mfr. of America v. Marty Jackley — Motion to file a reply to response,. Case filed August 25, 2026. [source] | September 25, 2026 |
| D.N.J. | CAREPOINT HEALTH MANAGEMENT ASSOCIATES LLC v. RWJ BARNABAS HEALTH INC. — Exhibit 4. Case filed September 6, 2022. [source] | September 25, 2026 |
| E.D. Mo. | AbbVie Inc. v. Hanaway — Memorandum and order: Accordingly, the Court grants Intervenors’ motion to intervene. see order for details. Case filed July 22, 2024. [source] | September 24, 2026 |
| M.D. Fla. | Florida Health Sciences Center, Inc. v. Eli Lilly and Company — Dismiss. Case filed July 2, 2026. [source] | September 21, 2026 |
| 8th Cir. | Novartis Pharmaceuticals Corp. v. Catherine L. Hanaway — Judge order: The petition for rehearing en banc is denied. The petition for panel rehearing is also denied. Case filed March 28, 2025. [source] | September 16, 2026 |
| 8th Cir. | AbbVie, Inc. v. Marty Jackley — Motion to hold briefing schedule in abeyance. Case filed August 11, 2026. [source] | September 15, 2026 |
| D.N.M. | AbbVie Inc. v. Torrez — Memorandum opinion and order granting Motion for Leave to File Amicus Curiae Brief; and denying Plaintiffs’ Motion for Preliminary Injunction. Case filed December 10, 2025. [source] | September 14, 2026 |
SOCIAL MEDIA & STAKEHOLDER SENTIMENT
Identified recent stakeholder and social commentary on the U.S. 340B Drug Pricing Program from the past 90 days, including reactions, statements, op-eds, and advocacy positions from hospital and health-center groups, provider and patient advocates, drug manufacturers, PBMs, and policy commentators, sourced from LinkedIn posts, Reddit (r/pharmacy, r/healthcare), Substack/newsletter opinions, and reputable news outlets.
340B Drug Pricing Program – NACHC
National Association of Community Health Centers (NACHC) · September 29, 2026
- Main theme: NACHC’s advocacy for the 340B program’s importance to Community Health Centers.
- Stakeholder sentiment: NACHC expresses concern over actions by drug companies that threaten patient access to critical medicines and essential health services supported by the 340B Program.
- Potential implications: Potential reduction in access to affordable medications and health services for underserved populations.
- Credibility: NACHC is a leading organization representing community health centers.
WHAT TO WATCH NEXT
- Johnson & Johnson’s compliance deadlines for 340B claims-data submission. [source]
- Federal pilot program for 340B rebates starting January 1, 2027. [source]
- Oklahoma’s appeal decision on its 340B Nondiscrimination Act. [source]
- Congressional response to AHA’s call for a permanent 340B rebate ban. [source]
End of briefing.
This briefing is provided for informational purposes only and does not constitute legal, regulatory, financial, or compliance advice. Automated summarization may contain errors or omissions, and source materials may change after publication. Recipients should independently verify all information against the cited primary sources before relying on it.
© 2026 MedMatrix Rx. All rights reserved.